‘No coding required’
ReSync provides AI-enabled drug discovery solutions to biotechs, coordinating labs, data and AI models on its platform. High-throughput virtual screening brings real-world lab-based insights into the digital environment, enhancing the accuracy of testing and modelling drug candidates.
The company plans to leverage NIMs to streamline the use of AI in R&D by managing the technical and user experience aspects. ReSync has integrated DiffDock, MolMIM and GenMol — Nvidia’s core small molecule NIM microservices — that it will use in combination with its own AI models, including Absorption, Distribution, Metabolism and Excretion (ADME) and Toxicity predictions. This combination of models will take users through the whole cycle of in silico analysis.
ReSync said that the partnership will ensure that its users can access the resources they need to work on their core research goals, without dealing with behind-the-scenes technology.
“AI has transformed digital drug discovery, but many biotechs and pharmas remain limited by their ability to deploy and manage AI infrastructure,” said Mihir Trivedi, CEO of ReSync Bio. “Integrating Nvidia BioNeMo helps bridge this gap by making advanced AI tools accessible to every drug discovery team — no coding required.”
‘Removing inefficiencies’
Sapio’s lab informatics platform hosts its cloud-based solutions — a Laboratory Information Management System (LIMS), Electronic Laboratory Notebook (ELN) and Scientific Data Management — that streamline workflows across R&D, clinical diagnostics and manufacturing.
With BioNeMo, the Sapio platform will provide access to embedded in silico tools, allowing researchers to rapidly identify and optimise drug candidates. With easy access to models, drug discoveries can be made faster and more efficiently, Sapio said.
“AI innovation is advancing rapidly, but scientists are often forced to navigate fragmented tools with complex interfaces, slowing down research,” said Kevin Cramer, CEO at Sapio. “Our integration of Nvidia’s powerful AI-driven tools directly into the Sapio Platform enables researchers to apply AI seamlessly into their experiments. Through this work, we are removing inefficiencies and equipping scientists with the tools to rapidly generate, analyse and visualise both chemical and biological results.”
Nvidia opened the BioNeMo framework to the global biopharma industry in November 2024. According to the company, over 200 techbios have already integrated BioNeMo into their drug discovery platforms. Last month, Nvidia released Evo2 on BioNeMo, a tool that offers insights into DNA, RNA and proteins across a wide range of species.